The global sinusitis treatment market is expected to thrive amid the rising prevalence of the condition, and growing need for better treatment options.
Market Analysis in Brief
Sinusitis is a common medical condition which has been affecting a significant population across the globe. This can be triggered by environmental and host factors including polluted air, smoke, animal dander, and dust. Noticeably, sinusitis is characterised by inflammation of the sinus lining caused by allergens, irritants, viruses, fungi, bacteria, and microbes. The affected patient often complains of nasal congestion, facial pain or pressure, postnasal drip, and headache. Acute sinusitis is caused by viruses and is usually self-limiting and is more common as compared to bacterial sinusitis. The viral sinusitis is more pervasive, and patients tend to recover without antibiotics. Nearly 90% of patients suffering from colds have an element of viral sinusitis, presenting a substantial demand for effective sinusitis treatment. This keeps the global sinusitis treatment market afloat.
Key Report Findings
- The sinusitis treatment market exceeded revenue of US$3 Bn in the year 2022
- Escalating need for timely diagnosis and effective treatment will fuel market expansion
- Mounting chronic sinusitis, and rhinosinusitis prevalence will account for accelerated growth of sinusitis treatment industry
- Sales of antibiotics surge ahead
- North America dominates, whereas Europe reflects higher growth potential
Growth Drivers
Pacing Demand for Diagnosis and Treatment
Sinusitis is a condition that can be categorized as either acute or chronic. In this condition, the nasal cavities are blocked or filled with fluid caused by diverse pathogens including bacteria and viruses. When sinusitis is left untreated, it can develop into either acute or chronic forms. Sinusitis can lead to complications associated with brain abscesses and meningitis. Early diagnosis and appropriate treatment are critical to prevent the occurrence of complications.
Blood tests, sinus CT scans, nasal cytology & allergy testing, ciliary function tests, and sinus MRIs are typically utilized in diagnosing the issues. First-line treatments include antibiotics, while decongestants and surgery are used at a severe stage. Against this backdrop, the growing rate of sinusitis prevalence and demand for diagnostic tests, tech developments in sinusitis surgery and antibiotics are set to advance the growth trajectory of the global sinusitis treatment market.
Rise in Prevalence of Rhinosinusitis
Over the recent past, the incidence of sinusitis has been on the rise. In the United States alone, there were 73 million restricted-activity days related to sinusitis, also known as rhinosinusitis, in a single year. Total direct medical costs went up to almost 2.4 billion excluding surgery or radiographic imaging. To this end, sinusitis is amongst the leading health conditions for antibiotics prescription, which contributes heavily toward the sinusitis treatment market growth.
Furthermore, according to the National Health Interview Survey, approximately 14.7% of individuals had sinusitis the preceding year. Perceptively, rhinosinusitis is classified as acute, subacute, recurrent acute, and chronic rhinosinusitis. Acute rhinosinusitis lasts less than 4 weeks with complete resolution, while subacute rhinosinusitis is a continuum of acute rhinosinusitis lasting less than 12 weeks.
Patients suffering from recurrent acute rhinosinusitis experience four or more acute episodes that last for a minimum of 7 days each, in any 1-year period. Meanwhile, the symptoms of chronic rhinosinusitis continue to persist for 12 weeks or longer. The long-lasting impact of rhinosinusitis hinders individuals from performing daily tasks and indicates high time for seeking treatment for a better quality of life. This will continue to complement the progression of the sinusitis treatment market.
Increasing Rate of Chronic Sinusitis Identification and Diagnosis
As symptoms of chronic sinusitis continue to prevail for more than 12 weeks, it is suggested to see the doctor. While this boosts the sinusitis treatment market revenue, based on an individual's health condition, a CT scan or MRI might be used to identify structural issues. Deviated nasal septum (the nose is shifted to the side), or polyps (growths) are included in structural problems associated with chronic sinusitis. At times, in a few cases, a biopsy is advised to see the spread of the infection. This involves an examination of tissues or bone samples.
Oftentimes, the similarity of sinusitis and other issues may restrain the identification of these issues. If an individual experiences persistent symptom such as headaches, toothaches, or facial pain, it is important for them to seek a medical evaluation from a healthcare provider or otolaryngologist. This is especially necessary if various therapies have been attempted but have not provided relief.
Overview of Key Segments
Antibiotics Segment to Demonstrate Considerable Growth
Some of the most prominent treatment options available in the sinusitis treatment market include Analgesics, Antihistamines, Corticosteroids, Antibiotics, and Surgery. Antibiotics are the most prescribed treatment for bacterial sinusitis. Bacterial sinusitis involves frontal, sphenoid, or ethmoid sinuses that may cause more serious issues. Long-time prescriptions include antibiotics such as penicillin, cephalosporin, and macrolide.
According to the World Health Organization, antibiotics, decongestants, or steroid nasal sprays may be referred to in case of chronic sinusitis. Augmentin, Zithromax, Septra, Levaquin, and Amoxil are common antibiotics for sinus infections. Nevertheless, there is a significant need to reimagine the approach to treatment, especially for adults.
Considering the development of novel drugs and therapies, substantial capital, efforts, scientific research, and time are required. Consequently, major market players are ramping up their R&D efforts to come up with much better and more efficacious alternatives for treating sinusitis among patients.
Growth Opportunities Across Regions
North America Reigns Supreme
Geographical dimensions of the global sinusitis treatment market extend the most towards North America. Attributing to this growth is the higher prevalence of rhinosinusitis in the region. In the United States alone, approximately, 35 million individuals are affected by rhinosinusitis every year. The region accounts for around 18 million office visits per year.
On the flip side, the market in Europe holds immense potential owing to the mounting invasive bacterial diseases and innovation in the diagnosis of bacterial infections. In addition, with the growing pervasiveness of bacterial and viral infections, Asia Pacific has also emerged as a growing market. Notwithstanding, the lack of awareness of sinusitis and available diagnostic options are expected to pose restrictions to the growth of the regional market.
Leading Participants in Sinusitis Treatment Industry
The key players operating in the global sinusitis treatment market include Medtronic plc, Stryker, Olympus Corporation, Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Sanofi SA, Intersect ENT, Inc., and Aurobindo Pharma among others.
Regional Classification of the Global Sinusitis Treatment Market is Described Below:
North America
- U.S.
- Canada
Europe
- Germany
- France
- Spain
- U.K.
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
1. Executive Summary
1.1. Global Sinusitis Treatment Market Outlook, 2018 - 2030 (US$ Million)
1.2. Global Sinusitis Treatment Market Incremental Opportunity, 2018 - 2030 (US$ Million)
1.3. Key Industry Trends
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.1.1. Driver 1
2.2.1.2. Driver 2
2.2.2. Restraints
2.2.2.1. Restraint 1
2.2.2.2. Restraint 2
2.2.3. Market Opportunities Matrix
2.3. Porters Five Forces Analysis
2.4. Regulatory Guidelines
2.5. Clinical Trials and Pipeline Overview
2.6. Covid-19 Impact Analysis
3. Global Sinusitis Treatment Market Outlook, 2018 - 2030
3.1. Global Sinusitis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Antihistamines
3.1.1.2. Corticosteroids
3.1.1.3. Analgesics
3.1.1.4. Antibiotics
3.1.1.5. Other
3.1.2. BPS Analysis/Market Attractiveness Analysis
4. Global Sinusitis Treatment Market Outlook, 2018 - 2030
4.1. Global Sinusitis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Chronic Sinusitis
4.1.1.2. Acute Sinusitis
4.1.1.3. Sub-Acute Sinusitis
4.1.2. BPS Analysis/Market Attractiveness Analysis
4.2. Global Sinusitis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Nasal
4.2.1.2. Oral
4.2.1.3. Injectable
4.2.1.4. Topical
4.2.2. BPS Analysis/Market Attractiveness Analysis
4.3. Global Sinusitis Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. North America
4.3.1.2. Europe
4.3.1.3. Asia Pacific
4.3.1.4. Rest of the World
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. North America Sinusitis Treatment Market Outlook, 2018 - 2030
5.1. North America Sinusitis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Antihistamines
5.1.1.2. Corticosteroids
5.1.1.3. Analgesics
5.1.1.4. Antibiotics
5.1.1.5. Other
5.1.2. BPS Analysis/Market Attractiveness Analysis
5.2. North America Sinusitis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Chronic Sinusitis
5.2.1.2. Acute Sinusitis
5.2.1.3. Sub-Acute Sinusitis
5.2.2. BPS Analysis/Market Attractiveness Analysis
5.3. North America Sinusitis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. Nasal
5.3.1.2. Oral
5.3.1.3. Injectable
5.3.1.4. Topical
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. North America Sinusitis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
5.4.1. Key Highlights
5.4.1.1. U.S.
5.4.1.2. Canada
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Europe Sinusitis Treatment Market Outlook, 2018 - 2030
6.1. Europe Sinusitis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2030
6.1.1. Key Highlights
6.1.1.1. Antihistamines
6.1.1.2. Corticosteroids
6.1.1.3. Analgesics
6.1.1.4. Antibiotics
6.1.1.5. Other
6.1.2. BPS Analysis/Market Attractiveness Analysis
6.2. Europe Sinusitis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Chronic Sinusitis
6.2.1.2. Acute Sinusitis
6.2.1.3. Sub-Acute Sinusitis
6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Europe Sinusitis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. Nasal
6.3.1.2. Oral
6.3.1.3. Injectable
6.3.1.4. Topical
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Europe Sinusitis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
6.4.1. Key Highlights
6.4.1.1. Germany
6.4.1.2. France
6.4.1.3. U.K.
6.4.1.4. Italy
6.4.1.5. Spain
6.4.1.6. Rest of Europe
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Asia Pacific Sinusitis Treatment Market Outlook, 2018 - 2030
7.1. Asia Pacific Sinusitis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Antihistamines
7.1.1.2. Corticosteroids
7.1.1.3. Analgesics
7.1.1.4. Antibiotics
7.1.1.5. Other
7.1.2. BPS Analysis/Market Attractiveness Analysis
7.2. Asia Pacific Sinusitis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Chronic Sinusitis
7.2.1.2. Acute Sinusitis
7.2.1.3. Sub-Acute Sinusitis
7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Asia Pacific Sinusitis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2030
7.3.1. Key Highlights
7.3.1.1. Nasal
7.3.1.2. Oral
7.3.1.3. Injectable
7.3.1.4. Topical
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Asia Pacific Sinusitis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
7.4.1. Key Highlights
7.4.1.1. China
7.4.1.2. Japan
7.4.1.3. India
7.4.1.4. South Korea
7.4.1.5. Australia & New Zealand
7.4.1.6. Rest of Asia Pacific
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Rest of the World Sinusitis Treatment Market Outlook, 2018 - 2030
8.1. Rest of the World Sinusitis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Antihistamines
8.1.1.2. Corticosteroids
8.1.1.3. Analgesics
8.1.1.4. Antibiotics
8.1.1.5. Other
8.1.2. BPS Analysis/Market Attractiveness Analysis
8.2. Rest of the World Sinusitis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Chronic Sinusitis
8.2.1.2. Acute Sinusitis
8.2.1.3. Sub-Acute Sinusitis
8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Rest of the World Sinusitis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2030
8.3.1. Key Highlights
8.3.1.1. Nasal
8.3.1.2. Oral
8.3.1.3. Injectable
8.3.1.4. Topical
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Rest of the World Sinusitis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
8.4.1. Key Highlights
8.4.1.1. Latin America
8.4.1.2. Middle East & Africa
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Market Share Analysis
9.2. Company Profiles
9.2.1. Pfizer, Inc.
9.2.1.1. Company Overview
9.2.1.2. Financial Overview
9.2.1.3. Treatment Type Portfolio
9.2.1.4. Recent Developments
*Above details will include, but not be limited to below list of companies based on availability
9.2.2. Abbott Laboratories
9.2.3. GSK plc
9.2.4. Novartis AG
9.2.5. Bayer AG
9.2.6. Fresenius Kabi AG
9.2.7. OptiNose US, Inc.
9.2.8. Lyra Therapeutics
9.2.9. Others
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
Download Sample Report
Member
Quality assured
